Skip to content

THAR

Tharimmune, Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.54
+6.63%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
R&D Expense3.1M3.1M6.4M3.6M2.3M
SG&A Expense17.0M17.0M6.0M5.9M4.6M
General & Admin Expense13.3M17.0M6.0M5.9M4.6M
Selling & Marketing Expense
Other Expenses
Total Operating Expenses20.1M20.1M12.4M9.5M6.9M
Cost and Expenses20.1M20.1M12.4M9.5M6.9M
Operating Income (EBIT)(20.1M)(20.1M)(12.4M)(9.5M)(6.9M)
Non-Operating
Interest Income41.4K41.4K249.9K152.6K
Interest Expense28.3K28.3K13.7K16.5K1.6M
Net Interest Income13.1K13.1K236.2K136.1K(1.6M)
Other Non-Op Income/Expense(22.0M)(22.0M)236.2K136.1K(1.6M)
Non-Operating Income (excl Interest)22.0M22.0M(222.5K)(152.6K)
EBT (Pre-Tax Income)(42.1M)(42.1M)(12.2M)(9.3M)(8.5M)
Income Tax Expense(6.2M)(6.2M)
Bottom Line
Net Income(35.9M)(35.9M)(12.2M)(9.3M)(8.5M)
Earnings from Cont. Ops(35.9M)(35.9M)(12.2M)(9.3M)(8.5M)
Earnings from Discont. Ops
Bottom Line Net Income(35.9M)(35.9M)(12.2M)(9.3M)(8.5M)
Per Share
Basic EPS($2.76)($1.12)($9.41)($107.08)($280.77)
Diluted EPS($2.76)($1.12)($9.41)($107.08)($280.77)
Revenue Per Share$0.00$0.00$0.00$0.00$0.00
Shares
Basic Shares Outstanding32.0M32.0M1.3M8702930178
Diluted Shares Outstanding32.0M32.0M1.3M8702930178
Profitability Metrics
EBITDA(42.1M)(42.1M)(12.4M)(9.1M)(6.7M)
D&A(222.5K)152.6K228.5K
EBIT(42.1M)(42.1M)(12.2M)(9.3M)(6.9M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025